Stephen J. Duffy

Stephen J. Duffy

Auto-generated profile, based on publicly available information

Stephen J. Duffy

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
WCWilliam Chan
William Chan
ATAndrew J. Taylor
Andrew J. Taylor
AEAndris H. Ellims
Andris H. Ellims
LLLisa Lefkovits
Lisa Lefkovits
CWChiew Wong
Chiew Wong
SDStephen J. Duffy
Stephen J. Duffy
Background—: Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxygen species by chelating redox-active iron and thereby may reduce ischemia-reperfusion injury and myocardial infarct (MI) size. We investigated whether DFO administered before reperfusion by primary percutaneous coronary intervention (PPCI) would ameliorate oxidative stress and MI size. Methods and Results—: We randomly assigned 60 patients with ST-elevation–MI to receive an intravenous bolus of DFO (500 mg) immediately before PPCI followed by a 12-hour infusion (50 mg/kg of body weight) (n=28) or normal saline bolus and infusion (placebo group, n=32). MI size was measured by contrast-enhanced cardiac MRI (CMRI; day 3±1), creatine kinase and troponin I area-under-the-curve, and severity of wall motion abnormality on echocardiography. Clinical follow-up including repeat CMRI and echocardiography were performed at 3 months (100±17 days). Oxidative stress was assessed by plasma F 2 -isoprostane levels. DFO and placebo groups were well balanced with respect to baseline characteristics, symptom- and door-to-balloon times, pre-PPCI coronary patency, and infarct-related artery location. Serum iron levels were decreased with DFO treatment after PPCI compared with placebo (3.0±2.5 versus 12.6±5.5 μmol/L, P <0.0001), which persisted until the end of the infusion. In DFO-treated patients, there was a significant reduction in plasma F 2 -isoprostane levels immediately after PPCI (2878±1461 versus 2213±579 pmol/L, P =0.04). However, there was no difference in CMRI-determined infarct size (DFO, 17.4±10.8%, versus placebo, 18.6±10.2%; P =0.73), myocardial salvage index at 3 days or at 3 months, or the area-under-the-curve for creatine kinase or troponin I. Conclusions—: Adjunctive DFO treatment after the onset of ischemia and continued periprocedurally ameliorates oxidative stress without limiting infarct size. Clinical Trial Registration—: URL: http://www.anzctr.org.au/ . Unique identifier: ACTRN12608000308392.

1 May 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
JZJennifer Zhou
Jennifer Zhou
DLDanny Liew
Danny Liew
SDStephen J. Duffy
Stephen J. Duffy
JSJames Shaw
James Shaw
AWAntony Walton
Antony Walton
DSDion Stub
Dion Stub
Background: There is increasing evidence that use of intravascular ultrasound (IVUS) guidance during percutaneous coronary intervention (PCI) is associated with improved clinical outcomes compared with angiography guidance alone. However, concern regarding the cost-effectiveness of IVUS has limited use of this technology worldwide. In this study, we aimed to evaluate the cost-effectiveness of IVUS-guided PCI compared with angiography-guided PCI in patients undergoing drug-eluting stent implantation. Methods: A decision-analytic Markov model was constructed to compare the cost-effectiveness of IVUS to angiography guidance from the Australian healthcare system perspective. Procedure-related morbidity and mortality were estimated from the literature. Costs were obtained from Australian sources. The population of interest was all-comers undergoing PCI with drug-eluting stent. Outcomes of interest included costs, life-expectancy, and quality-adjusted life years (QALYs) for both treatment groups. Results: In the base case, IVUS guidance was cost-effective compared with angiography guidance alone. With 5% annual discounting, IVUS was associated with increased lifetime costs of Australian dollars (AUD) $823 (USD $597) per person and benefits of 0.04 life years and 0.05 QALYs compared with angiography, yielding an incremental cost-effectiveness ratio of AUD $17 539 (USD $12 730) per QALY gained. Results were robust to sensitivity analyses, with IVUS being cost-effective in 99% of 10 000 Monte Carlo iterations assuming a willingness-to-pay threshold of AUD $50 000 per QALY gained. In a worst-case scenario analysis, IVUS remained the cost-effective option, with an ICER of AUD $36 651 (USD $26 601) per QALY gained. Exploratory subgroup analysis revealed that cost-effectiveness may be greatest among patients with left main and complex coronary lesions. Conclusions: Use of IVUS guidance during PCI is likely to be cost-effective compared with angiography guidance alone among patients undergoing drug-eluting stent implantation.

6 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JSJulia Stehli
Julia Stehli
DDDiem Dinh
Diem Dinh
MDMisha Dagan
Misha Dagan
SDStephen J. Duffy
Stephen J. Duffy
ABAngela Brennan
Angela Brennan
SZSarah Zaman
Sarah Zaman
Background: Women with ST‐segment–elevation myocardial infarction experience delays in reperfusion compared with men with little data on each time component from symptom onset to reperfusion. This study analyzed sex discrepancies in patient delays, prehospital system delays, and hospital delays. Methods and Results: Consecutive patients with ST‐segment–elevation myocardial infarction treated with percutaneous coronary intervention across 30 hospitals in the Victorian Cardiac Outcomes Registry (2013–2018) were analyzed. Data from the Ambulance Victoria Data warehouse were used to perform linkage to the Victorian Cardiac Outcomes Registry for all patients transported via emergency medical services (EMS). The primary end point was EMS call‐to‐door time (prehospital system delay). Secondary end points included symptom‐to‐EMS call time (patient delay), door‐to‐device time (hospital delay), 30‐day mortality, major adverse cardiovascular events, and major bleeding. End points were analyzed according to sex and adjusted for age, comorbidities, cardiogenic shock, cardiac arrest, and symptom onset time. A total of 6330 (21% women) patients with ST‐segment–elevation myocardial infarction were transported by EMS. Compared with men, women had longer adjusted geometric mean symptom‐to‐EMS call times (47.0 versus 44.0 minutes; P <0.001), EMS call‐to‐door times (58.1 versus 55.7 minutes; P <0.001), and door‐to‐device times (58.5 versus 54.9 minutes; P =0.006). Compared with men, women had higher 30‐day mortality (odds ratio [OR], 1.38; 95% CI, 1.06–1.79; P =0.02) and major bleeding (OR, 1.54; 95% CI, 1.08–2.20; P =0.02). Conclusions: Female patients with ST‐segment–elevation myocardial infarction experienced excess delays in patient delays, prehospital system delays, and hospital delays, even after adjustment for confounders. Prehospital system and hospital delays resulted in an adjusted excess delay of 10 minutes compared with men.

1 February 2003 in Current Opinion in Lipidology
Verified
Journal Article
Closed access
SDStephen J. Duffy
Stephen J. Duffy
JVJoseph A. Vita
Joseph A. Vita
There continues to be considerable interest in the concept that antioxidant therapy may reduce cardiovascular risk. Phenols have antioxidant properties and may be important micronutrients. Epidemiological studies have demonstrated a strong link between phenolic intake and reduced cardiovascular risk, but the mechanism of benefit has not been determined. Recent evidence has emerged that a number of phenolic compounds, particularly flavonoids, reverse vascular endothelial dysfunction. The normal endothelium plays a critical role in regulating vascular function, and endothelial dysfunction is associated with increased cardiovascular risk. The present article reviews the links between phenolic intake, endothelial function and cardiovascular risk. Endothelium-derived nitric oxide bioactivity appears to be increased by supplementation with a number of phenols, and this may explain some of the favourable effects of high phenolic intake seen in epidemiological studies.

1 June 2019 in JACC
Verified
Journal Article
Closed access
JWJosephine Warren
Josephine Warren
SNShane Nanayakkara
Shane Nanayakkara
NANick Andrianopoulos
Nick Andrianopoulos
ABAngela Brennan
Angela Brennan
DDDiem Dinh
Diem Dinh
JYJ. Yeoh
J. Yeoh

1 June 2019 in American Heart Journal
Verified
Journal Article
Closed access
MYMatias B. Yudi
Matias B. Yudi
DCDavid J. Clark
David J. Clark
OFOmar Farouque
Omar Farouque
NANick Andrianopoulos
Nick Andrianopoulos
AAAndrew E. Ajani
Andrew E. Ajani
SDStephen J. Duffy
Stephen J. Duffy